| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 14 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 7.39M | $441.12M | - | |
| CEO | 890.4K | $53.16M | - | |
| CEO | 875.0K | $52.24M | - | |
| Other | 740.2K | $44.19M | - | |
| COO | 215.3K | $12.85M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2025 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 3,250 | $18.69 | $60,737.55 | -6.6% | +9.3% | +127.3% | |
| Apr 21, 2025 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 5,000 | $16.07 | $80,365.82 | -0.2% | +34.8% | - | |
| Apr 17, 2025 | Kintz Samuel50 | President And CEO | Sell | 5,000 | $16.42 | $82,096.00 | -0.5% | +29.8% | - | |
| Apr 7, 2025 | Patel Anish53 | Chief Operating Officer | Sell | 6,667 | $18.04 | $120,268.73 | -0.7% | +9.6% | +141.5% | |
| Mar 27, 2025 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 3,250 | $21.33 | $69,320.88 | -12.4% | -0.0% | +80.5% | |
| Mar 24, 2025 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 1,000 | $22.50 | $22,504.50 | -4.2% | -9.7% | +38.7% | |
| Mar 19, 2025 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 12,500 | $20.61 | $257,575.00 | -1.2% | +4.4% | +43.8% | |
| Mar 17, 2025 | Kintz Samuel50 | President And CEO | Sell | 12,500 | $20.83 | $260,320.00 | -1.2% | +9.7% | +32.1% | |
| Mar 7, 2025 | Patel Anish53 | Chief Operating Officer | Sell | 6,667 | $21.44 | $142,936.48 | -2.0% | +1.8% | +40.2% | |
| Feb 27, 2025 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 3,250 | $20.41 | $66,326.98 | -20.0% | -20.2% | +47.3% |